https://orcid.org/0000-0002-5243-2556
References
- Gomollón F, Dignass A, Annese V, ECCO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
- Cohn HM, Dave M, Loftus EV. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1301–1315.
- Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
- Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis. 2019;25(5):831–842.
- Pillai N, Dusheiko M, Maillard MH, et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis. 2019;13(6):744–754.
- Jackson BD, Gray K, Knowles SR, et al. EHealth technologies in inflammatory bowel disease: a systematic review. ECCOJC. 2016;10(9):1103–1121.
- Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
- Venkatesh V, Morris MG, Davis GB, et al. User acceptance of information technology: toward a unified view. Mis Q. 2003;27:425–478.
- Clara I, Lix L, Walker J, et al. The Manitoba IBD index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol. 2009;104(7):1754–1764.
- Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1(8167):514.
- Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006;12(4):304–310.
- Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43(1):29–32.
- Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(10):1081–1088.
- Pedersen N, Elkjaer M, Duricova D, et al. EHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012;36(9):840–849.
- Pedersen N, Thielsen P, Martinsen L, et al. EHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20(12):2276–2285.
- Cross RK, Langenberg P, Regueiro M, et al. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol. 2019;114(3):472–482.
- de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–968.
- McCombie A, Walmsley R, Barclay M, et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflamm Bowel Dis. 2020;26(7):1098–1109.
- Cross RK, Cheevers N, Rustgi A, et al. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2012;18(6):1018–1025.
- Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “‘Constant-care’ approach”. Gut. 2010;59(12):1652–1661.
- Hunter J, Claridge A, James S, et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad Med J. 2012;88(1042):487–491.
- Timmers T, Janssen L, Kool RB, et al. Educating patients by providing timely information using smartphone and tablet apps: systematic review. J Med Internet Res. 2020;22(4):e17342.
- Abutaleb A, Buchwald A, Chudy-Onwugaje K, et al. Inflammatory bowel disease telemedicine clinical trial: impact of educational text messages on disease-specific knowledge over 1 year. Inflamm Bowel Dis. 2018;24(10):2191–2197.